{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:01:44Z","timestamp":1761897704505,"version":"3.37.3"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005389","name":"Universit\u00e0 degli Studi dell'Insubria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005389","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose of Review<\/jats:title><jats:p>Philadelphia-negative myeloproliferative neoplasms (MPNs) include polycythemia vera (PV), essential thrombocythemia (ET), prefibrotic (pre-), and overt-primary myelofibrosis (primary MF, PMF). PV and ET could evolve into secondary MF (SMF), whose early diagnosis relies on monitoring signs of possible progression. All MPNs have a risk of blast phase (BP), that is associated with a very dismal outcome. Overall survival (OS) is different among MPNs, and disease-specific prognostic scores should be applied for a correct clinical management. In this review, an overview of current prognostic scores in MPNs will be provided.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent Findings<\/jats:title><jats:p>The biological complexity of MPNs and its role on the trajectory of disease outcome have led to the design of integrated prognostic models that are nowadays of common use in PMF patients. As for PV and ET, splicing gene mutations could have a detrimental role, but with the limit of the not routinary recommended application of extensive molecular analysis in these diseases. SMF is recognized as a distinct entity compared to PMF, and OS estimates should be calculated by the MYSEC-PM (<jats:italic>Myelofibrosis SECondary-prognostic model<\/jats:italic>). Both in PMF and SMF, decisions as selection of patients potentially candidates to allogenic stem cell transplant or that could benefit from an early shift from standard treatment are based not only on conventional prognostic scores, but also on multivariable algorithms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>The expanding landscape of risk prediction for OS, evolution to BP, and SMF progression from PV\/ET informs personalized approach to the management of patients affected by MPNs.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s11899-022-00672-6","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T10:04:44Z","timestamp":1662026684000},"page":"127-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms"],"prefix":"10.1007","volume":"17","author":[{"given":"Barbara","family":"Mora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"672_CR1","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The\u00a02016\u00a0revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.","DOI":"10.1182\/blood-2016-03-643544"},{"key":"672_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M, MCInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328.","journal-title":"Annu Rev Med"},{"issue":"2","key":"672_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Versovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437\u20138.","journal-title":"Leukemia"},{"key":"672_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.leukres.2018.04.012","volume":"69","author":"B Mora","year":"2018","unstructured":"Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, et al. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leuk Res. 2018;69:100\u20132.","journal-title":"Leuk Res"},{"issue":"10","key":"672_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","volume":"117","author":"F Passamonti","year":"2004","unstructured":"Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755\u201361.","journal-title":"Am J Med"},{"issue":"6","key":"672_CR6","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, et al. International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737\u201340.","journal-title":"Leuk Res"},{"key":"672_CR7","doi-asserted-by":"publisher","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","volume":"42","author":"RM Shallis","year":"2020","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map. Blood Rev. 2020;42:100706.","journal-title":"Blood Rev"},{"issue":"3","key":"672_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","volume":"63","author":"S Verstovsek","year":"2022","unstructured":"Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022;63(3):694\u2013702.","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"672_CR9","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507\u201313.","journal-title":"Blood"},{"issue":"23","key":"672_CR10","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179\u201384.","journal-title":"J Clin Oncol"},{"issue":"9","key":"672_CR11","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874\u201381.","journal-title":"Leukemia"},{"issue":"9","key":"672_CR12","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703\u20138.","journal-title":"Blood"},{"key":"672_CR13","doi-asserted-by":"crossref","unstructured":"Passamonti F, Giorgino T, Mora B,\u00a0Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2726-31.","DOI":"10.1038\/leu.2017.169"},{"issue":"12","key":"672_CR14","doi-asserted-by":"publisher","first-page":"E451","DOI":"10.1002\/ajh.26362","volume":"96","author":"GM Dores","year":"2021","unstructured":"Dores GM, Curtis RE, Linet MS, Morton LM. Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001\u20132017. Am J Hematol. 2021;96(12):E451\u20134.","journal-title":"Am J Hematol"},{"key":"672_CR15","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Parasuraman S, Yu J, Shah A, Kumar S, Xi A, et al. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. Ann Hematol. 2022;101(1):131-37.","DOI":"10.1007\/s00277-021-04682-x"},{"key":"672_CR16","doi-asserted-by":"crossref","unstructured":"Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, et al. Improved\u00a0survival\u00a0of patients with\u00a0myelofibrosis\u00a0in the last decade: single-center experience. Cancer. 2022;128(8):1658-65.","DOI":"10.1002\/cncr.34103"},{"issue":"2","key":"672_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/MOH.0000000000000218","volume":"23","author":"F Passamonti","year":"2016","unstructured":"Passamonti F, Mora B, Maffioli M. New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms. Curr Opin Hematol. 2016;23(2):137\u201343.","journal-title":"Curr Opin Hematol"},{"key":"672_CR18","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis:\u00a0COMFORT-I and -II\u00a0pooled analyses. J Hematol Oncol. 2017;10(1):156.","DOI":"10.1186\/s13045-017-0527-7"},{"key":"672_CR19","doi-asserted-by":"crossref","unstructured":"Pardanani A, Tefferi A, Masszi T, Mishchenko E, Drummond M, Jourdan E, et al. Updated results of the placebo-controlled, phase III JAKARTA trial of\u00a0fedratinib in patients with intermediate-2 or high-risk\u00a0myelofibrosis. Br J Haematol. 2021;195(2):244-48.","DOI":"10.1111\/bjh.17727"},{"key":"672_CR20","doi-asserted-by":"crossref","unstructured":"McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, et al. Allogeneic haematopoietic cell transplantation for\u00a0myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia. 2021;35(9):2445-59.","DOI":"10.1038\/s41375-021-01294-2"},{"issue":"3","key":"672_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/s41375-021-01449-1","volume":"36","author":"S Kunte","year":"2022","unstructured":"Kunte S, Rybicki L, Viswabandya A, Tamari R, Bashey A, Keyzner A, et al. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. Leukemia. 2022;36(3):856\u201364.","journal-title":"Leukemia"},{"key":"672_CR22","doi-asserted-by":"crossref","unstructured":"Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, et al. Driver\u00a0mutations\u2019\u00a0effect\u00a0in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia. 2017;31(4):970-73.","DOI":"10.1038\/leu.2016.351"},{"issue":"5","key":"672_CR23","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/s41375-020-01053-9","volume":"35","author":"B Mora","year":"2021","unstructured":"Mora B, Siracusa C, Rumi E, Maffioli M, Casetti IC, Barraco D, et al. Platelet count predicts driver mutations\u2019 co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis. Leukemia. 2021;35(5):1490\u20133.","journal-title":"Leukemia"},{"key":"672_CR24","doi-asserted-by":"crossref","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. N Engl J Med. 2018;379(15):1416-30.","DOI":"10.1056\/NEJMoa1716614"},{"issue":"15","key":"672_CR25","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/bloodadvances.2020002414","volume":"4","author":"PE Debureaux","year":"2020","unstructured":"Debureaux PE, Cassinat B, Soret-Dulphy J, Mora B, Verger E, Maslah N, et al. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Adv. 2020;4(15):3708\u201315.","journal-title":"Blood Adv"},{"key":"672_CR26","doi-asserted-by":"crossref","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057-69.","DOI":"10.1038\/s41375-018-0077-1"},{"key":"672_CR27","unstructured":"Network NCC. Myeloproliferative neoplasms. 2022 [Available from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf]."},{"issue":"12","key":"672_CR28","doi-asserted-by":"publisher","first-page":"E464","DOI":"10.1002\/ajh.26377","volume":"96","author":"CJ Smith","year":"2021","unstructured":"Smith CJ, Thomas JW, Ruan G, Hyun MC, Bansal R, McLaughlin N, et al. A population-based study of outcomes in polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the United States from 2001 to 2015: comparison with data from a Mayo Clinic single institutional series. Am J Hematol. 2021;96(12):E464\u20138.","journal-title":"Am J Hematol"},{"key":"672_CR29","doi-asserted-by":"publisher","first-page":"106809","DOI":"10.1016\/j.leukres.2022.106809","volume":"115","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shah A, Xi A, et al. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res. 2022;115:106809.","journal-title":"Leuk Res"},{"issue":"6","key":"672_CR30","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diag- nosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197\u2013201.","journal-title":"Blood"},{"issue":"4","key":"672_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.5045\/br.2021.2021089","volume":"56","author":"A-J Lee","year":"2021","unstructured":"Lee A-J, Kim S-G, Nam JY, Yun J, Ryoo H-M, Bae CH. Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden. Blood Res. 2021;56(4):259\u201365.","journal-title":"Blood Res"},{"issue":"3","key":"672_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-022-00639-z","volume":"12","author":"N Gangat","year":"2022","unstructured":"Gangat N, Jadoon Y, Szuber N, Hanson CA, Wolanskyj-Spinner AP, Ketterling RP, et al. Cytogenetic abnormalities in essential thrombocythemia: clinical and molecular correlates and prognostic relevance in 809 informative cases. Blood Cancer J. 2022;12(3):44.","journal-title":"Blood Cancer J"},{"issue":"3","key":"672_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/17474086.2019.1585239","volume":"12","author":"B Mora","year":"2019","unstructured":"Mora B, Passamonti F. Developments in diagnosis and treatment of essential thrombocythemia. Expert Rev Hematol. 2019;12(3):159\u201371.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"672_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00277-020-04287-w","volume":"100","author":"F Palandri","year":"2021","unstructured":"Palandri F, Mora B, Gangat N, Catani L. Is there a gender effect in polycythemia vera? Ann Hematol. 2021;100(1):11\u201325.","journal-title":"Ann Hematol"},{"issue":"3","key":"672_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjh.14798","volume":"182","author":"D Barraco","year":"2018","unstructured":"Barraco D, Cerquozzi S, Hanson CA, Ketterling RP, Pardanani AD, Gangat N, et al. Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance. Br J Haematol. 2018;182(3):437\u201340.","journal-title":"Br J Haematol"},{"issue":"5","key":"672_CR36","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/cncr.21297","volume":"104","author":"F Passamonti","year":"2005","unstructured":"Passamonti F, Rumi E, Arcaini L, Castagnola C, Lunghi M, Bernasconi P, et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer. 2005;104(5):1032\u20136.","journal-title":"Cancer"},{"issue":"19","key":"672_CR37","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1182\/blood.2019003347","volume":"135","author":"L Ronner","year":"2020","unstructured":"Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O\u2019Connell C, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020;135(19):1696\u2013703.","journal-title":"Blood"},{"issue":"12","key":"672_CR38","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1182\/bloodadvances.2019001407","volume":"4","author":"T Karantanos","year":"2020","unstructured":"Karantanos T, Chaturvedi S, Braunstein EM, Spivak J, Resar L, Karanika S, et al. Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. Blood Adv. 2020;4(12):2567\u201376.","journal-title":"Blood Adv"},{"issue":"1","key":"672_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21\u201330.","journal-title":"Blood Adv"},{"issue":"3","key":"672_CR40","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","volume":"97","author":"A Sen\u00edn","year":"2018","unstructured":"Sen\u00edn A, Fern\u00e1ndez-Rodr\u00edguez C, Bellosillo B, Camacho L, Longar\u00f3n R, Angona A, et al. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Ann Hematol. 2018;97(3):443\u201351.","journal-title":"Ann Hematol"},{"key":"672_CR41","doi-asserted-by":"crossref","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189(2):291-302.","DOI":"10.1111\/bjh.16380"},{"issue":"3","key":"672_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11899-018-0453-y","volume":"13","author":"F Passamonti","year":"2018","unstructured":"Passamonti F, Mora B, Barraco D, Maffioli M. Post-ET and Post-PV Myelofibrosis: updates on a Distinct Prognosis from Primary Myelofibrosis. Curr Hematol Malig Rep. 2018;13(3):173\u201382.","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"672_CR43","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-018-0088-y","volume":"32","author":"E Masselli","year":"2018","unstructured":"Masselli E, Carubbi C, Camb\u00f2 B, Pozzi G, Gobbi G, Mirandola P, et al. The -2518 A\/G polymorphism of the monocyte chemoattractant protein-1 as a candidate genetic predisposition factor for secondary myelofibrosis and biomarker of disease severity. Leukemia. 2018;32(10):2266\u201370.","journal-title":"Leukemia"},{"issue":"10","key":"672_CR44","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1038\/s41375-020-0767-3","volume":"34","author":"F Ferrer-Mar\u00edn","year":"2020","unstructured":"Ferrer-Mar\u00edn F, Arroyo AB, Bellosillo B, Cuenca EJ, Zamora L, Hern\u00e1ndez-Rivas JM, et al. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. Leukemia. 2020;34(10):2648\u201359.","journal-title":"Leukemia"},{"issue":"11","key":"672_CR45","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3324\/haematol.13346","volume":"93","author":"F Passamonti","year":"2008","unstructured":"Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645\u201351.","journal-title":"Haematologica"},{"issue":"2","key":"672_CR46","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431\u20138.","journal-title":"Leukemia"},{"issue":"5","key":"672_CR47","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ajh.24338","volume":"91","author":"YC Elala","year":"2016","unstructured":"Elala YC, Lasho T, Gangat N, Finke C, Barraco D, Haider M, et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016;91(5):503\u20136.","journal-title":"Am J Hematol"},{"issue":"10","key":"672_CR48","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1038\/bcj.2016.98","volume":"6","author":"M Haider","year":"2016","unstructured":"Haider M, Elala YC, Gangat N, Hanson CA, Tefferi A. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. Blood Cancer J. 2016;6(10):e487.","journal-title":"Blood Cancer J"},{"issue":"11","key":"672_CR49","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/ajh.26332","volume":"96","author":"GG Loscocco","year":"2021","unstructured":"Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, et al. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1607 patients. Am J Hematol. 2021;96(11):1472\u201380.","journal-title":"Am J Hematol"},{"issue":"5","key":"672_CR50","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1365-2141.2009.07804.x","volume":"146","author":"A Alvarez-Larran","year":"2009","unstructured":"Alvarez-Larran A, Bellosillo B, Martinez-Aviles L, Saumell S, Salar A, Abella E, et al. Post polycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol. 2009;146(5):504\u20139.","journal-title":"Br J Haematol"},{"issue":"3","key":"672_CR51","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1038\/bcj.2017.17","volume":"7","author":"D Barraco","year":"2017","unstructured":"Barraco D, Cerquozzi S, Hanson CA, Ketterling RP, Pardanani A, Gangat N, et al. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017;7(3):e538.","journal-title":"Blood Cancer J"},{"issue":"12","key":"672_CR52","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.3324\/haematol.2020.264143","volume":"106","author":"M Schino","year":"2021","unstructured":"Schino M, Fiorentino V, Rossi E, Betti S, Di Cecca M, Ranucci V, et al. Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms. Haematologica. 2021;106(12):3162\u20139.","journal-title":"Haematologica"},{"issue":"5","key":"672_CR53","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/bjh.13886","volume":"172","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"Alvarez-Larr\u00e1n A, Kerguelen A, Hern\u00e1ndez-Boluda JC, P\u00e9rez-Encinas M, Ferrer-Mar\u00edn F, B\u00e1rez A, et al. Frequency and prognostic value of resistance\/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172(5):786\u201393.","journal-title":"Br J Haematol"},{"issue":"9","key":"672_CR54","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","volume":"35","author":"G Abu-Zeinah","year":"2021","unstructured":"Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35(9):2592\u2013601.","journal-title":"Leukemia"},{"issue":"9","key":"672_CR55","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera:the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574\u20139.","journal-title":"Leukemia"},{"issue":"13","key":"672_CR56","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901.","journal-title":"Blood"},{"issue":"4","key":"672_CR57","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"672_CR58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/leu.2010.234","volume":"25","author":"D Caramazza","year":"2011","unstructured":"Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011;25(1):82\u20138.","journal-title":"Leukemia"},{"key":"672_CR59","doi-asserted-by":"crossref","unstructured":"Guglielmelli\u00a0P,\u00a0Pacilli\u00a0A,\u00a0Rotunno\u00a0G, Rumi E, Rosti V, Delaini F,\u00a0et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.\u00a0Blood\u00a02017; 129(24):3227-36.","DOI":"10.1182\/blood-2017-01-761999"},{"issue":"3","key":"672_CR60","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bjh.17617","volume":"194","author":"A Bankar","year":"2021","unstructured":"Bankar A, Alibhai S, Smith E, Yang D, Malik S, Cheung V, et al. Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study. Br J Haematol. 2021;194(3):557\u201367.","journal-title":"Br J Haematol"},{"key":"672_CR61","doi-asserted-by":"crossref","unstructured":"Sochacki AL, Bejan CA, Zhao S, Patel A, Kishtagari A, Spaulding TP, et al. Patient-specific comorbidities as prognostic variables for survival in\u00a0myelofibrosis. Blood Adv. 2022 Apr 14; online ahead of print.","DOI":"10.1182\/bloodadvances.2021006318"},{"issue":"7","key":"672_CR62","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472\u20137.","journal-title":"Leukemia"},{"issue":"9","key":"672_CR63","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861\u20139.","journal-title":"Leukemia"},{"key":"672_CR64","doi-asserted-by":"crossref","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol. 2018;36(4):310-18.","DOI":"10.1200\/JCO.2017.76.4886"},{"key":"672_CR65","doi-asserted-by":"crossref","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for primary myelofibrosis. J Clin Oncol. 2018;36(17):1769\u201370.","DOI":"10.1200\/JCO.2018.78.9867"},{"key":"672_CR66","doi-asserted-by":"crossref","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018;32(7):1631-42.","DOI":"10.1038\/s41375-018-0107-z"},{"issue":"7","key":"672_CR67","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ajh.26548","volume":"97","author":"F Mannelli","year":"2022","unstructured":"Mannelli F, Bencini S, Coltro G, Loscocco GG, Peruzzi B, Rotunno G, et al. Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. Am J Hematol. 2022;97(7):846\u201355.","journal-title":"Am J Hematol"},{"key":"672_CR68","doi-asserted-by":"crossref","unstructured":"Luque Paz D, Riou J, Verger E, Cassinat B, Chauveau A, Ianotto JC, et al. Genomic analysis of\u00a0primary\u00a0and secondary\u00a0myelofibrosis\u00a0redefines the prognostic impact of ASXL1 mutations: a FIM study. Blood Adv. 2021;5(5):1442-51.","DOI":"10.1182\/bloodadvances.2020003444"},{"key":"672_CR69","doi-asserted-by":"crossref","unstructured":"Guglielmelli P,\u00a0Coltro G, Mannelli F, Rotunno G, Loscocco GG, Mannarelli C, et al. ASXL1 mutations are prognostically significant in primary myelofibrosis, but not myelofibrosis following essential thrombocythemia or polycythemia vera. Blood Adv. 2022;6(9):2927-31.","DOI":"10.1182\/bloodadvances.2021006350"},{"issue":"15","key":"672_CR70","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","volume":"4","author":"G Coltro","year":"2020","unstructured":"Coltro G, Rotunno G, Mannelli L, Mannarelli C, Fiaccabrino S, Romagnoli S, et al. RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features. Blood Adv. 2020;4(15):3677\u201387.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"672_CR71","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood-2021-146600","volume":"138","author":"G Coltro","year":"2021","unstructured":"Coltro G, Mannelli F, Loscocco GG, Mannarelli C, Rotunno G, Maccari C, et al. Phenotype Is Associated with Distinctive Molecular Features and Adverse Outcomes in Patients with Myelofibrosis. Abstract from the 2021 American Society of Hematology (ASH) Congress. Blood. 2021;138(Supplement 1):1498.","journal-title":"Blood"},{"issue":"8","key":"672_CR72","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/ijms20081839","volume":"20","author":"A Iurlo","year":"2019","unstructured":"Iurlo A, Cattaneo D, Gianelli U. Blast transformation in myeloproliferative neoplasms: risk factors, biological findings, and targeted therapeutic options. Int J Mol Sci. 2019;20(8):1839.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"672_CR73","doi-asserted-by":"publisher","first-page":"5612","DOI":"10.1182\/blood-2010-11-320002","volume":"117","author":"R Vaidya","year":"2011","unstructured":"Vaidya R, Caramazza D, Begna KH, Gangat N, Van Dyke DL, Hanson CA, et al. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood. 2011;117(21):5612\u20135.","journal-title":"Blood"},{"issue":"15","key":"672_CR74","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","volume":"116","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood. 2010;116(15):2857\u20138.","journal-title":"Blood"},{"issue":"2","key":"672_CR75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Finke CM, Elala Y, Hanson CA, Ketterling RP, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105\u201311.","journal-title":"Blood Adv"},{"key":"672_CR76","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","volume":"59","author":"L Masarova","year":"2017","unstructured":"Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, et al. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017;59:110\u20136.","journal-title":"Leuk Res"},{"issue":"12","key":"672_CR77","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1038\/leu.2017.268","volume":"31","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Saeed L, Hanson CA, Ketterling RP, Pardanani A, Gangat N. Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. Leukemia. 2017;31(12):2851\u20132.","journal-title":"Leukemia"},{"key":"672_CR78","doi-asserted-by":"crossref","unstructured":"Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, et al. Value of\u00a0cytogenetic\u00a0abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018;103(9):e392-94.","DOI":"10.3324\/haematol.2017.185751"},{"issue":"10","key":"672_CR79","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-018-0128-x","volume":"8","author":"D Barraco","year":"2018","unstructured":"Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, et al. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018;8(10):89.","journal-title":"Blood Cancer J"},{"issue":"1","key":"672_CR80","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ajh.25644","volume":"95","author":"B Mora","year":"2020","unstructured":"Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, et al. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC group. Am J Hematol. 2020;95(1):E1\u20133.","journal-title":"Am J Hematol"},{"issue":"7","key":"672_CR81","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ajh.24377","volume":"91","author":"G Rotunno","year":"2016","unstructured":"Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, et al. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group. Am J Hematol. 2016;91(7):681\u20136.","journal-title":"Am J Hematol"},{"key":"672_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100914","volume":"54","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Corrao G, Castellani G, Mora B, Maggioni G, Gale RP, et al. The future of research in hematology: integration of conventional studies with real-world data and artificial intelligence. Blood Rev. 2022;54: 100914.","journal-title":"Blood Rev"},{"issue":"21","key":"672_CR83","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","volume":"125","author":"N Kr\u00f6ger","year":"2015","unstructured":"Kr\u00f6ger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125(21):3347\u201350.","journal-title":"Blood"},{"issue":"11","key":"672_CR84","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/leu.2015.233","volume":"29","author":"NM Kr\u00f6ger","year":"2015","unstructured":"Kr\u00f6ger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group. Leukemia. 2015;29(11):2126\u201333.","journal-title":"Leukemia"},{"key":"672_CR85","doi-asserted-by":"crossref","unstructured":"Passamonti F. Stem cell transplant in MF: it\u2019s time to personalize. Blood.\u00a02019;133(20):2118-20.","DOI":"10.1182\/blood-2019-03-900860"},{"key":"672_CR86","doi-asserted-by":"crossref","unstructured":"Gagelmann N,\u00a0Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, et al. Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133(20):2233-42.","DOI":"10.1182\/blood-2018-12-890889"},{"key":"672_CR87","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger N, Sbianchi G, Sirait T, Wolschke C, Beelen D, Passweg J, et al. Impact of prior JAK-inhibitor therapy with\u00a0ruxolitinib\u00a0on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia. 2021;35(12):3551-60.","DOI":"10.1038\/s41375-021-01276-4"},{"key":"672_CR88","doi-asserted-by":"crossref","unstructured":"Ali H, Bacigalupo A. 2021 Update on allogeneic hematopoietic stem cell transplant for\u00a0myelofibrosis: a review of current data and applications on risk stratification and management. Am J Hematol. 2021;96(11):1532-38.","DOI":"10.1002\/ajh.26349"},{"issue":"9","key":"672_CR89","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"9","key":"672_CR90","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"Supplement1","key":"672_CR91","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1182\/blood-2021-150894","volume":"138","author":"S Verstovsek","year":"2021","unstructured":"Verstovsek S, Kiladjian J-J, Vannucchi AM, Mesa RA, Scherber RM, Hamer-Maansson JE, et al. Does early intervention in myelofibrosis impact outcomes? A pooled analysis of the COMFORT I and II studies Abstract from the 2021 American Society of Hematology (ASH) Congress. Blood. 2021;138(Supplement1):1505.","journal-title":"Blood"},{"issue":"12","key":"672_CR92","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","volume":"123","author":"F Passamonti","year":"2014","unstructured":"Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014;123(12):1833\u20135.","journal-title":"Blood"},{"key":"672_CR93","doi-asserted-by":"crossref","unstructured":"Guglielmelli P,\u00a0Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, et al. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Adv. 2022;6(2):373-75.","DOI":"10.1182\/bloodadvances.2021006006"},{"issue":"9","key":"672_CR94","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139\u201345.","journal-title":"Haematologica"},{"key":"672_CR95","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.leukres.2018.10.001","volume":"74","author":"F Palandri","year":"2018","unstructured":"Palandri F, Palumbo GA, Bonifacio M, Breccia M, Latagliata R, Martino B, et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: results from a multicentre study on 284 patients. Leuk Res. 2018;74:86\u20138.","journal-title":"Leuk Res"},{"issue":"10","key":"672_CR96","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.3109\/10428194.2016.1146950","volume":"57","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali HK, Stalbovskaya V, Gopalakrishna P, Perez-Ronco J, Foltz L. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leuk Lymphoma. 2016;57(10):2464\u2013547.","journal-title":"Leuk Lymphoma"},{"key":"672_CR97","doi-asserted-by":"crossref","unstructured":"Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, et al. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Adv. 2022;6(6):1855-64.","DOI":"10.1182\/bloodadvances.2021006889"},{"issue":"13","key":"672_CR98","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/cncr.34216","volume":"128","author":"F Palandri","year":"2022","unstructured":"Palandri F, Bartoletti D, Iurlo A, Bonifacio M, Abruzzese E, Caocci G, et al. Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. Cancer. 2022;128(13):2449\u201354.","journal-title":"Cancer"},{"issue":"5","key":"672_CR99","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.clml.2020.12.024","volume":"21","author":"L Masarova","year":"2021","unstructured":"Masarova L, Bose P, Pemmaraju N, Daver N, Zhou L, Pierce S, et al. Clinical significance of bone marrow blast percentage in patients with myelofibrosis and the effect of ruxolitinib therapy. Clin Lymphoma Myeloma Leuk. 2021;21(5):318\u201327.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"672_CR100","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2217\/fon-2021-1358","volume":"18","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Heidel FH, Parikh RC, Ajmera M, Tang D, Nadal JA, et al. Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review. Future Oncol. 2022;18(18):2217\u201331.","journal-title":"Future Oncol"},{"issue":"6","key":"672_CR101","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","volume":"126","author":"KP Patel","year":"2015","unstructured":"Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015;126(6):790\u20137.","journal-title":"Blood"},{"issue":"20","key":"672_CR102","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/bloodadvances.2017009530","volume":"1","author":"JY Spiegel","year":"2017","unstructured":"Spiegel JY, McNamara C, Kennedy JA, Panzarella T, Arruda A, Stockley T, et al. Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1\/2 inhibitor therapy. Blood Adv. 2017;1(20):1729\u201338.","journal-title":"Blood Adv"},{"key":"672_CR103","doi-asserted-by":"crossref","unstructured":"Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, et al. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018;97(3):435-41.","DOI":"10.1007\/s00277-017-3194-4"},{"issue":"5","key":"672_CR104","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/bloodadvances.2020003614","volume":"5","author":"S Rontauroli","year":"2021","unstructured":"Rontauroli S, Castellano S, Guglielmelli P, Zini R, Bianchi E, Genovese E, et al. Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Adv. 2021;5(5):1452\u201362.","journal-title":"Blood Adv"},{"issue":"19","key":"672_CR105","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.3390\/cancers13194744","volume":"13","author":"S Fantini","year":"2021","unstructured":"Fantini S, Rontauroli S, Sartini S, Mirabile M, Bianchi E, Badii F, et al. Increased plasma levels of lncRNAs LINC01268, GAS5 and MALAT1 correlate with negative prognostic factors in myelofibrosis. Cancers (Basel). 2021;13(19):4744.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"672_CR106","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/antiox11010113","volume":"11","author":"E Genovese","year":"2022","unstructured":"Genovese E, Mirabile M, Rontauroli S, Sartini S, Fantini S, Tavernari L, et al. The response to oxidative damage correlates with driver mutations and clinical outcome in patients with myelofibrosis. Antioxidants (Basel). 2022;11(1):113.","journal-title":"Antioxidants (Basel)"},{"issue":"13","key":"672_CR107","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/cncr.34205","volume":"128","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, et al. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer. 2022;128(13):2420\u201332.","journal-title":"Cancer"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00672-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-022-00672-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00672-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T19:38:56Z","timestamp":1676662736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-022-00672-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":107,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1007\/s11899-022-00672-6","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"type":"print","value":"1558-8211"},{"type":"electronic","value":"1558-822X"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"22 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}